PERKIN-ELMER BEEFING UP PROTEIN ANALYSIS OFFERINGS THROUGH $360 MIL. PERSEPTIVE BIOSYSTEMS ACQUISITION; DEAL TO CLOSE BY END OF YEAR
This article was originally published in The Gray Sheet
Perkin-Elmer's $360 mil. acquisition of PerSeptive Biosystems would combine PerSeptive's strength in advanced protein analysis technology with PE's broad line of DNA sequencing technologies. The combination would create a fully integrated technology platform in the field of biomedical research and drug discovery, PE says.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.